This was a game changer in terms of validity of the Volpara product. The market didn't think so. This should have reached new highs, however it didn't.
Many investors think like me. This is an overheated stock that lacks the fundamentals to support its quality product. They may need to rethink how they advise the market of news that has the potential to change its industry in its favour.
Sales projections were missing and as were complementing AI solutions. Maybe management will get it right next time. Today's reaction was the market's verdict.
- Forums
- ASX - By Stock
- VHT
- Ann: Volpara DENSE trial results published
Ann: Volpara DENSE trial results published, page-9
Featured News
Add VHT (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online